Patents by Inventor Howard Levin

Howard Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230360512
    Abstract: A system, method, and apparatus are provided to facilitate social distancing. The system issues alarms based on the distance between a user and an object and one or more variable social distancing thresholds. The system enables trade-offs between risk and a desire to have in-person interaction for different activities by using one or more variable social distancing thresholds that may be based on social distancing guidelines and various characteristics.
    Type: Application
    Filed: June 29, 2023
    Publication date: November 9, 2023
    Inventor: Howard Levin
  • Patent number: 11806073
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: November 7, 2023
    Assignee: Axon Therapies, Inc.
    Inventors: Anisha Bapna, Zoar Jacob Engelman, Howard Levin, Pajhand Iranitalab, Casey Andrew Miller, Thomas Ryan McGrath, Manuel Arzadon Javier, Jr.
  • Patent number: 11809059
    Abstract: A system and method including, receiving a plurality of optical beams in a first direction along a first plane in a first beam pattern towards an optical element based on a trajectory that causes at least a portion of the plurality of optical beams to not contact a surface of the optical lens. The system and method includes transmitting a first set of the plurality of optical beams in the first direction along a second plane. The system and method includes transmitting a second set of the plurality of optical beams in the first direction along the first plane. The system and method includes generating a second beam pattern by transmitting the first set and the second set of the plurality of optical beams through an optical element, wherein the second beam pattern adjusts the trajectory to cause the portion to contact the surface of the optical lens.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: November 7, 2023
    Assignee: Aeva, Inc.
    Inventors: Bradley Scot Levin, Keith Gagne, Neal N. Oza, Cameron Howard
  • Patent number: 11801092
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: October 31, 2023
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
  • Patent number: 11759639
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: September 19, 2023
    Assignee: BackBeat Medical, LLC
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 11712296
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: August 1, 2023
    Assignee: Axon Therapies, Inc.
    Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung, Howard Levin
  • Publication number: 20230233817
    Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.
    Type: Application
    Filed: January 9, 2023
    Publication date: July 27, 2023
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 11704990
    Abstract: A system, method, and apparatus are provided to facilitate social distancing. The system issues alarms based on the distance between a user and an object and one or more variable social distancing thresholds. The system enables trade-offs between risk and a desire to have in-person interaction for different activities by using one or more variable social distancing thresholds that may be based on social distancing guidelines and various characteristics.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: July 18, 2023
    Inventor: Howard Levin
  • Patent number: 11696985
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: July 11, 2023
    Assignee: Reprieve Cardiovascular, Inc.
    Inventors: Andrew V. Halpert, Mark Tauscher, Mark Gelfand, Howard Levin
  • Patent number: 11675085
    Abstract: A system and method include receiving a first beam pattern from an optical source that comprises a plurality of optical beams transmitted towards a target causing different spaces to form between each optical beam. The system and method include measuring a vertical angle between at least two of the optical beams along a first axis and calculating a second beam pattern based on the vertical angle and a pivot point that causes the optical beams to be transmitted towards the target with substantially uniform spacing. The system and method include adjusting, at the pivot point, one or more components to form the second beam pattern to adjust the plurality of different spaces to the substantially uniform spacing for transmission towards the target. The system and method include receiving return optical beams from the target to produce a plurality of points to form the point cloud.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: June 13, 2023
    Assignee: Aeva, Inc.
    Inventors: Cameron Howard, Sawyer Isaac Cohen, Keith Gagne, Bradley Scot Levin, Pierre Hicks
  • Publication number: 20230165634
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 1, 2023
    Inventors: Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan McGRATH, Manuel Arzadon JAVIER, Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Nicholas C. VanDILLEN, Anne Marie AHONEN
  • Publication number: 20230158308
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.
    Type: Application
    Filed: November 22, 2022
    Publication date: May 25, 2023
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 11577059
    Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: February 14, 2023
    Assignee: BackBeat Medical, LLC
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 11529520
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 20, 2022
    Assignee: BackBeat Medical, LLC
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 11504185
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: November 22, 2022
    Assignee: Axon Therapies, Inc.
    Inventors: Pajhand Iranitalab, Casey Andrew Miller, Thomas Ryan McGrath, Manuel Arzadon Javier, Anisha Bapna, Zoar Jacob Engelman, Howard Levin, Nicholas C. VanDillen, Anne Marie Ahonen
  • Publication number: 20220338924
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Application
    Filed: July 5, 2022
    Publication date: October 27, 2022
    Inventors: Howard LEVIN, Mark GELFAND
  • Publication number: 20220323142
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: December 17, 2021
    Publication date: October 13, 2022
    Applicant: Axon Therapies, Inc.
    Inventors: Mark GELFAND, Howard LEVIN, Daniel Alexander SMITH, Ali SHAJII
  • Publication number: 20220257315
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 18, 2022
    Inventors: Howard LEVIN, Mark GELFAND, Zoar Jacob ENGELMAN, Dorin PANESCU, Mark S. LEUNG
  • Patent number: 11413090
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: August 16, 2022
    Assignee: Axon Therapies, Inc.
    Inventors: Pajhand Iranitalab, Casey Andrew Miller, Thomas Ryan McGrath, Manuel Arzadon Javier, Jr., Anisha Bapna, Zoar Jacob Engelman, Howard Levin, Nicholas C. VanDillen, Anne Marie Ahonen
  • Publication number: 20220230525
    Abstract: A system, method, and apparatus are provided to facilitate social distancing. The system issues alarms based on the distance between a user and an object and one or more variable social distancing thresholds. The system enables trade-offs between risk and a desire to have in-person interaction for different activities by using one or more variable social distancing thresholds that may be based on social distancing guidelines and various characteristics.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 21, 2022
    Inventor: Howard Levin